Table 4.
Summary of the results of MLPA analyses of TCF3-PBX1 positive and negative BCP-ALL patients in the JACLS ALL02 and CCLSG cohorts
| JACLS ALL02 cohort | CCLSG cohort | |||||
|---|---|---|---|---|---|---|
| TCF3-PBX1 (+) | TCF3-PBX1 (−) | P-value | TCF3-PBX1 (+) | TCF3-PBX1 (−) | P-value | |
| Number of patients | 53 | 163 | 22 | 155 | ||
| IKZF1 deletion (%) | 2 (3.8) | 17 (10.4) | <0.001 | 1 (4.5) | 21 (13.5) | 0.23 |
| CDKN2A deletion (%) | 10 (18.9) | 71 (43.6) | <0.001 | 6 (27.3) | 37 (23.9) | 0.73 |
| CDKN2B deletion (%) | 8 (15.1) | 61 (37.4) | <0.001 | 5 (22.7) | 40 (25.8) | 0.76 |
| PAX5 deletion (%) | 12 (22.6) | 47 (28.8) | 0.37 | 9 (40.9) | 28 (18.1) | 0.014 |
| ETV6 deletion (%) | 1 (1.9) | 46 (28.2) | <0.001 | 2 (9.1) | 40 (25.8) | 0.085 |
| RB1 deletion (%) | 9 (17.0) | 3 (1.8) | <0.001 | 4 (18.2) | 20 (12.9) | 0.50 |
| BTG1 deletion (%) | 1 (1.9) | 14 (8.6) | <0.001 | 1 (4.5) | 20 (12.9) | 0.26 |
| EBF1 deletion (%) | 2 (3.8) | 20 (12.3) | <0.001 | 2 (9.1) | 17 (10.9) | 0.79 |
JACLS, Japan Association of Childhood Leukemia Study; CCLSG, Children's Cancer and Leukemia Study Group.